Michael Morrissey Exelixis, Inc. (EXEL) insider trading activity

Michael Morrissey is President and CEO of EXELIXIS, INC.. Currently has a direct ownership of 1.52 Million shares of EXEL, which is worth approximately $68.1 Million. The most recent transaction as insider was on Aug 15, 2023, when has been sold 23,304 shares (Common Stock) at a price of $21.51 per share, resulting in proceeds of $501,269. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 1.52M

6.46% 3M change

57.43% 12M change

Total Value Held $68.1 Million

MICHAEL MORRISSEY Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Aug 15 2023	SELL Payment of exercise price or tax liability	$501,269 $21.51 p/Share	23,304 Reduced 3.83%	585,496 Common Stock
May 15 2023	SELL Payment of exercise price or tax liability	$642,875 $19.18 p/Share	33,518 Reduced 5.22%	608,800 Common Stock
Apr 03 2023	BUY Grant, award, or other acquisition	-	313,185 Added 32.78%	642,318 Common Stock
Feb 15 2023	SELL Payment of exercise price or tax liability	$208,317 $18.08 p/Share	11,522 Reduced 3.38%	329,133 Common Stock
Jan 30 2023	SELL Bona fide gift	-	37,994 Reduced 10.03%	340,655 Common Stock
Jan 24 2023	SELL Payment of exercise price or tax liability	$1,076,424 $17.36 p/Share	62,006 Reduced 14.07%	378,649 Common Stock
Jan 24 2023	BUY Exercise of conversion of derivative security	$420,000 $4.2 p/Share	100,000 Added 18.5%	440,655 Common Stock
Dec 07 2022	SELL Bona fide gift	-	106,010 Reduced 23.73%	340,655 Common Stock
Nov 15 2022	SELL Payment of exercise price or tax liability	$389,409 $16.71 p/Share	23,304 Reduced 4.96%	446,665 Common Stock
Aug 03 2022	SELL Payment of exercise price or tax liability	$500,803 $21.49 p/Share	23,304 Reduced 4.72%	469,969 Common Stock
Aug 03 2022	BUY Grant, award, or other acquisition	-	94,002 Added 16.01%	493,273 Common Stock
Mar 04 2022	BUY Grant, award, or other acquisition	-	270,415 Added 40.38%	399,271 Common Stock
Feb 15 2022	SELL Payment of exercise price or tax liability	$1,211,083 $18.59 p/Share	65,147 Reduced 33.58%	128,856 Common Stock
Dec 15 2021	SELL Payment of exercise price or tax liability	$208,012 $17.0 p/Share	12,236 Reduced 5.63%	205,006 Common Stock
Dec 15 2021	BUY Grant, award, or other acquisition	-	46,478 Added 17.62%	217,242 Common Stock
Nov 29 2021	SELL Bona fide gift	-	196,524 Reduced 53.51%	170,764 Common Stock
Nov 15 2021	SELL Payment of exercise price or tax liability	$3,507,418 $18.1 p/Share	193,780 Reduced 34.54%	367,288 Common Stock
Oct 22 2021	SELL Payment of exercise price or tax liability	$527,854 $21.33 p/Share	24,747 Reduced 4.22%	561,068 Common Stock
Oct 22 2021	BUY Grant, award, or other acquisition	-	94,002 Added 13.83%	585,815 Common Stock
May 14 2021	SELL Bona fide gift	-	19,722 Reduced 3.86%	491,813 Common Stock
May 12 2021	SELL Payment of exercise price or tax liability	$761,794 $25.16 p/Share	30,278 Reduced 5.59%	511,535 Common Stock
May 12 2021	BUY Exercise of conversion of derivative security	$210,000 $4.2 p/Share	50,000 Added 8.45%	541,813 Common Stock
Feb 24 2021	SELL Bona fide gift	-	67,374 Reduced 12.05%	491,813 Common Stock
Feb 15 2021	SELL Payment of exercise price or tax liability	$214,477 $21.91 p/Share	9,789 Reduced 1.72%	559,187 Common Stock
Feb 03 2021	SELL Payment of exercise price or tax liability	$1,470,686 $22.56 p/Share	65,190 Reduced 10.28%	568,976 Common Stock

Also insider at

VERA

Vera Therapeutics, Inc. Healthcare